TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,887,800 | -41.8% | 7,370,000 | 0.0% | 2.54% | -51.5% |
| Q2 2023 | $113,203,200 | -18.1% | 7,370,000 | +19.9% | 5.24% | -7.7% |
| Q1 2023 | $138,252,057 | +43.5% | 6,147,268 | +34.2% | 5.68% | +40.3% |
| Q4 2022 | $96,359,460 | -2.2% | 4,582,000 | +14.6% | 4.05% | -10.4% |
| Q3 2022 | $98,560,000 | +13.6% | 4,000,000 | +11.7% | 4.51% | -20.8% |
| Q2 2022 | $86,760,000 | +7.4% | 3,580,700 | +14.2% | 5.70% | +10.1% |
| Q1 2022 | $80,776,000 | +6.2% | 3,134,503 | +27.9% | 5.18% | -3.5% |
| Q4 2021 | $76,048,000 | – | 2,450,000 | – | 5.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |